Our demonstration of the lack of parallelism between endogenous tau in AD CSF compared to recombinant tau in surrogate matrix suggest that differences in tau surrogate peptide abundances may only be compared within one surrogate peptide between samples, as opposed to comparing the abundance of N-Terminus peptides compared to Mid-domain and C-Terminus peptides. This evidence concerns the gene MAPT and Alzheimer disease.